|Articles|November 1, 2000

Clinical and Economic Impact of Low-Molecular Weight Heparins in Managed Care
Volume 6
Issue 20 Suppl

Outpatient-Based Treatment Protocols in the Management of Venous Thromboembolic Disease

Author(s)Alex C. Spyropoulos, MD

Download PDF: Outpatient-Based Treatment Protocols in the Management of Venous Thromboembolic Disease

Articles in this issue

over 25 years ago

Article

Participating Faculty

over 25 years ago

Article

Introduction

over 25 years ago

Article

Overview of Enoxaparin in the Treatment of DVT

over 25 years ago

Article

DVT and Pulmonary Embolism in the Perioperative Patient

over 25 years ago

Article

CME/CPE Article: Economics of Low-Molecular Weight Heparins

over 25 years ago

Article

CME/CPE Quiz

over 25 years ago

Article

Selected Abstracts

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Outpatient-Based Treatment Protocols in the Management of Venous Thromboembolic Disease

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

Health Equity & Access Weekly Roundup: July 10, 2026

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

INCA033989 May Address Unmet Need in Mutant Calreticulin Myelofibrosis: Claire Harrison, MD

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Outpatient-Based Treatment Protocols in the Management of Venous Thromboembolic Disease

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

Health Equity & Access Weekly Roundup: July 10, 2026

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

INCA033989 May Address Unmet Need in Mutant Calreticulin Myelofibrosis: Claire Harrison, MD